TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37889180

Group type: EXPERIMENTAL
Intervention: Genetically determined pericardial adipose tissue (PAT)
Number of subjects: 28161

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 28161
Study: 37889196

Group type: EXPERIMENTAL
Intervention: 3-month transitional, tailored, progressive, multidomain physical rehabilitation intervention
Number of subjects: 0
Study: 37889198

Group type: EXPERIMENTAL
Intervention: Qualitative assessments through 8 semistructured virtual focus groups
Number of subjects: 42
Study: 37889203

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37889298

Group type: EXPERIMENTAL
Intervention: TLP thresholds -30%/+30%
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: TLP
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PSA serum value
Number of subjects: 102
Study: 37889308

Group type: EXPERIMENTAL
Intervention: 24-week exercise intervention during BEP-chemotherapy (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 24-week exercise intervention after BEP-chemotherapy (group B)
Number of subjects: 30
Study: 37889382

Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule
Number of subjects: 12
Study: 37889486

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel daily
Number of subjects: 5204

Group type: COMPARATOR
Intervention: Placebo gel daily
Number of subjects: 5204
Study: 37889487

Group type: EXPERIMENTAL
Intervention: 8-hour Time-Restricted Eating (TRE)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Daily Calorie Restriction (CR)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 37889513

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A malaria vaccine
Number of subjects: 0
Study: 37889522

Group type: EXPERIMENTAL
Intervention: BI 685509 (2 mg BID)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BI 685509 (3 mg BID)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BI 685509 (1, 2, or 3 mg BID)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BI 685509
Number of subjects: 64
Study: 37889525

Group type: EXPERIMENTAL
Intervention: Transdiagnostic mobile app intervention (exercises supporting emotion regulation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control intervention (health information snippet)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transdiagnostic mobile app intervention
Number of subjects: 200
Study: 37889541

Group type: EXPERIMENTAL
Intervention: Varenicline + Oral NRT (VAR+NRT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Smartphone medication reminders (REM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Varenicline alone (VAR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Varenicline + Oral NRT (VAR+NRT) with reminders (REM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall medication adherence (assessed via the Medication Adherence Questionnaire)
Number of subjects: 34
Study: 37889550

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37889573

Group type: EXPERIMENTAL
Intervention: Plant-Based Protein Intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37889619

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 101
Study: 37889867

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37889898

Group type: EXPERIMENTAL
Intervention: Elective surgical intervention for sLSS
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: In vivo experiment to elicit paraspinal muscle fatigue
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Measurements of muscle size and quality
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Physical activity level assessment
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Remote assessment of physical activity level and PROMs
Number of subjects: 122
Study: 37889928

Group type: EXPERIMENTAL
Intervention: Cervical screening for HPV16
Number of subjects: 3568938

Group type: EXPERIMENTAL
Intervention: Cervical screening for HPV18
Number of subjects: 3568938

Group type: EXPERIMENTAL
Intervention: Cervical screening for HPV35,39,51,56,59,66,68
Number of subjects: 3568938

Group type: EXPERIMENTAL
Intervention: Cervical screening for HPV16 in women below 30 years
Number of subjects: 3568938

Group type: EXPERIMENTAL
Intervention: Cervical screening for HPV35,39,51,56,59,66,68 in women below 30 years
Number of subjects: 3568938
Study: 37890035

Group type: EXPERIMENTAL
Intervention: Triglyceride-glucose index (TyG)
Number of subjects: 29960

Group type: COMPARATOR
Intervention: Low-density lipoprotein (LDL) levels < 100 mg/dL
Number of subjects: 29960
Study: 37890117

Group type: EXPERIMENTAL
Intervention: DS B-ALL patients
Number of subjects: 743
Study: 37890143

Group type: EXPERIMENTAL
Intervention: 5-minute physician-delivered brief counseling session on tobacco cessation using the 5A's strategy, in addition to usual care
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care for patients with diabetes
Number of subjects: 126
Study: 37890149

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 270
Study: 37890345

Group type: EXPERIMENTAL
Intervention: Niraparib and dostarlimab
Number of subjects: 41
Study: 37890351

Group type: EXPERIMENTAL
Intervention: Nivolumab (360 mg) plus eribulin (1.4 mg/m²)
Number of subjects: 90
Study: 37890671

Group type: EXPERIMENTAL
Intervention: Placental FPN protein abundance
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: PIDI (Placental iron deficiency index)
Number of subjects: 263
Study: 37890673

Group type: EXPERIMENTAL
Intervention: Higher energy density (ED) meals
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lower energy density (ED) meals
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Meal portions served
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Eating occasions and menus
Number of subjects: 94
Study: 37890839

Group type: EXPERIMENTAL
Intervention: Culturally modified Lifestyle intervention (n = 45)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Health and Wellness intervention (n = 55)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher postpartum sports/exercise (regardless of intervention arm)
Number of subjects: 100
Study: 37890879

Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 153
Study: 37890960

Group type: EXPERIMENTAL
Intervention: Xylitol syrup (two times per day for 6 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo syrup with sorbitol (two times per day for 6 months)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo syrup with sorbitol
Number of subjects: 250
Study: 37890966

Group type: EXPERIMENTAL
Intervention: Implantable loop recorders (ILR) and continuous glucose monitoring (CGM) for 18 months follow-up
Number of subjects: 70
Study: 37890981

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided distal radial fracture manipulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham ultrasound manipulation
Number of subjects: 120
Study: 37890987

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with medical care in No-IVT stratum
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with medical care in IVT stratum
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) in IVT stratum
Number of subjects: 202

Group type: COMPARATOR
Intervention: No-Endovascular therapy (No-EVT) in IVT stratum
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) in No-IVT stratum
Number of subjects: 202

Group type: COMPARATOR
Intervention: No-Endovascular therapy (No-EVT) in No-IVT stratum
Number of subjects: 202
Study: 37891072

Group type: EXPERIMENTAL
Intervention: One cycle of treatment (Cohort A, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two cycles of treatment (Cohort B, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to treatment
Number of subjects: 20
Study: 37891146

Group type: EXPERIMENTAL
Intervention: Exercise group (20-week exercise program: minimum of 3 supervised 90-minute sessions/week of aerobic plus resistance training)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Exercise group (20-week exercise program)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (usual routines)
Number of subjects: 77
Study: 37891178

Group type: EXPERIMENTAL
Intervention: EPP-AF® (900 mg/day for 10 days)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: EPP-AF®
Number of subjects: 188
Study: 37891206

Group type: EXPERIMENTAL
Intervention: Couple-based health education (group health education, home visits, print health messages alongside usual care)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 37891226

Group type: EXPERIMENTAL
Intervention: Zinc and vitamin E supplementation (1200 IU vitamin E and 120 mg elemental zinc the day before surgery, followed by 30 mg zinc and 200 IU vitamin E daily from the 2nd day after surgery to 3 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Zinc and vitamin E supplementation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 37891464

Group type: EXPERIMENTAL
Intervention: Bodily Pain (BP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Vitality (VT)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Social Functioning (SF)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: General Health (GH)
Number of subjects: 148
Study: 37891471

Group type: EXPERIMENTAL
Intervention: HIV-infected women on Tenofovir/Lamivudine/Efavirenz regimen
Number of subjects: 1208

Group type: COMPARATOR
Intervention: HIV-uninfected women
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: HBV-exposed infants
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Maternal factors (HIV-infection, tooth extractions)
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1208
Study: 37891513

Group type: EXPERIMENTAL
Intervention: Graphic warning labels
Number of subjects: 184

Group type: COMPARATOR
Intervention: Text-only warning labels
Number of subjects: 184
Study: 37891522

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine combined with cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline, vortioxetine, or duloxetine (for nonresponders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole, olanzapine, or lithium carbonate added to fluoxetine (for nonresponders)
Number of subjects: 0
Study: 37891531

Group type: EXPERIMENTAL
Intervention: Verum acupuncture at true acupuncture points plus usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture at non-acupuncture points plus usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 120
Study: 37891549

Group type: EXPERIMENTAL
Intervention: 2% HA gel with PBMT (diode laser 980 nm, 0.2 W)
Number of subjects: 26

Group type: COMPARATOR
Intervention: PBMT (diode laser 980 nm, 0.2 W) only
Number of subjects: 26
Study: 37891566

Group type: EXPERIMENTAL
Intervention: Non-adherence to medication
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Concerns about medication
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Beliefs about overprescribing medication
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Symptom burden and severity
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Common symptoms reported
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Associations between non-adherence and beliefs/symptoms
Number of subjects: 385
Study: 37891574

Group type: EXPERIMENTAL
Intervention: Perioperative mental health (PMH) bundle including behavioral activation (BA) and medication optimization (MO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptations to the PMH bundle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort-specific adaptations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compassion as an intervention element
Number of subjects: 0
Study: 37891608

Group type: EXPERIMENTAL
Intervention: PACAP (0.1 mg/ml, 6 μl, intranasally for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sirtuin3 knockdown
Number of subjects: 0
Study: 37891616

Group type: EXPERIMENTAL
Intervention: Oral fosfomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ciprofloxacin
Number of subjects: 0
Study: 37891623

Group type: EXPERIMENTAL
Intervention: Cardiac index (CI) measurement
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Mixed venous oxygen saturation (SvO2) measurement
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Combined low SvO2 and CI
Number of subjects: 565
Study: 37891643

Group type: EXPERIMENTAL
Intervention: Ultrasound-based device delivering brief, 30-millisecond pulses of low-intensity ultrasound into the subcallosal cingulate cortex every 4 seconds.
Number of subjects: 1
Study: 37891681

Group type: EXPERIMENTAL
Intervention: PEERNaija app (Arm 1) - includes daily medication reminders, peer-based social incentives, and virtual peer social support.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEERNaija + (Arm 2) - includes all features of Arm 1 plus a conditional financial incentive based on adherence performance.
Number of subjects: 0
Study: 37891699

Group type: EXPERIMENTAL
Intervention: Rules-based tool for cardiovascular disease prevention recommendations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guidelines, expert consensus, and medical society scientific statements
Number of subjects: 0
Study: 37892305

Group type: EXPERIMENTAL
Intervention: Contingent mother's voice intervention before or after cardiac surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive exposure to the mother's voice after surgery (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contingent mother's voice intervention
Number of subjects: 0
Study: 37892527

Group type: EXPERIMENTAL
Intervention: Standard nutritional counseling plus carbohydrate-last food order counseling (FO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard nutritional counseling (C)
Number of subjects: 45
Study: 37892573

Group type: EXPERIMENTAL
Intervention: Norepinephrine Zero-Bolus High-Infusion (Group ZBHI, 0 µg/0.1 µg kg)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Norepinephrine (other dosing schemes not specified)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study: 37892656

Group type: EXPERIMENTAL
Intervention: Whole-body vibration intervention on an oscillating platform for 12 weeks, 3 nonconsecutive days per week, 12 minutes per session.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal life with emphasis on glycemic controls before and after daily physical exercise.
Number of subjects: 0
Study: 37892785

Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Conventional Stenting (CS)
Number of subjects: 446
Study: 37893039

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37893050

Group type: EXPERIMENTAL
Intervention: Pancreatic Stone Protein (PSP)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Daily change of PSP
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Daily change of CRP
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Daily change of PCT
Number of subjects: 209
Study: 37893240

Group type: EXPERIMENTAL
Intervention: Fatty Liver Index (FLI) > 66
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pre-OLT smoking
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cut-off value of FLI
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Adverse cardiovascular events
Number of subjects: 110
Study: 37894280

Group type: EXPERIMENTAL
Intervention: Transcriptomics-based immunoscore (CD3+ and CD8+ T cell density)
Number of subjects: 522
Study: 37894368

Group type: EXPERIMENTAL
Intervention: Post-operative morbidity in LMICs (N=672)
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Post-operative morbidity in HICs (N=1009)
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Pre-operative mechanical bowel preparation
Number of subjects: 1820
Study: 37894732

Group type: EXPERIMENTAL
Intervention: Sirolimus (0.5-2 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus (low dosages)
Number of subjects: 0
Study: 37895218

Group type: EXPERIMENTAL
Intervention: Occult macular dysfunction syndrome (OMD)
Number of subjects: 0
Study: 37896812

Group type: EXPERIMENTAL
Intervention: Anakinra added to standard of care (SoC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 37896832

Group type: EXPERIMENTAL
Intervention: Higher HIV-1 Env gp120-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity
Number of subjects: 72
Study: 37897201

Group type: EXPERIMENTAL
Intervention: High care burden
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: ≥41 hr spent caregiving per week (reference 10-20 hr)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Self-efficacy for caregiving
Number of subjects: 152
Study: 37897388

Group type: EXPERIMENTAL
Intervention: Non-urgent patients who died within 30 days
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Causes of death among non-urgent patients
Number of subjects: 335
Study: 37897395

Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction injection
Number of subjects: 22
Study: 37897452

Group type: EXPERIMENTAL
Intervention: Healthy Eating Index-2015 (HEI-2015) scores at baseline
Number of subjects: 192
Study: 37897472

Group type: EXPERIMENTAL
Intervention: Infusion of allogeneic off-the-shelf CD45RA T cells
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study: 37897566

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Prebiotic treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: D. welbionis abundance
Number of subjects: 106

Group type: COMPARATOR
Intervention: In vitro effect of metformin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: D. welbionis J115 in mice
Number of subjects: 106
Study: 37897713

Group type: EXPERIMENTAL
Intervention: High-resolution diffusion-weighted imaging (hrDWI) (slice thickness: 2.5-3 mm)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Standard diffusion-weighted imaging (standard DWI) (slice thickness: 5-6 mm)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: High-resolution diffusion-weighted imaging (hrDWI)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Standard diffusion-weighted imaging (standard DWI)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Comparison of hrDWI vs. standard DWI
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: MRI field strength (1.5 T vs. 3 T)
Number of subjects: 321
Study: 37897800

Group type: EXPERIMENTAL
Intervention: Influenza patients with probable IAPA
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Influenza patients with IAPA
Number of subjects: 55

Group type: COMPARATOR
Intervention: Influenza patients without IAPA
Number of subjects: 55
Study: 37897866

Group type: EXPERIMENTAL
Intervention: ctDNA profiling using the Foundation One Liquid CDx Assay (324 genes, blood tumour mutational burden [bTMB], microsatellite instability status)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Matched therapy recommended by multidisciplinary tumor board (MTB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Treatment based on genomic profiling
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: FGFR3 alterations
Number of subjects: 140
Study: 37897888

Group type: EXPERIMENTAL
Intervention: Prior falls
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Impaired Timed Up and Go score
Number of subjects: 541
Study: 37898137

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents
Number of subjects: 1300
Study: 37898146

Group type: EXPERIMENTAL
Intervention: Oral PrEP (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Dapivirine ring
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Overall trial results
Number of subjects: 247
Study: 37898148

Group type: EXPERIMENTAL
Intervention: BNT162b2 BA.4/5 bivalent booster
Number of subjects: 123419

Group type: EXPERIMENTAL
Intervention: BNT162b2 BA.4/5 bivalent booster for XBB-related infections
Number of subjects: 123419

Group type: COMPARATOR
Intervention: At least two doses of wild-type mRNA vaccine alone
Number of subjects: 123419
Study: 37898152

Group type: EXPERIMENTAL
Intervention: Restful Jaw device (PEP Design; Saint Paul)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Dental Assistant (DA) support
Number of subjects: 169
Study: 37898184

Group type: EXPERIMENTAL
Intervention: Ozanimod (OZA), oral, once daily, incremental dosage for a maximum of 14 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 43
Study: 37898410

Group type: EXPERIMENTAL
Intervention: CS-2034 low-dose (30 μg of mRNA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CS-2034 high-dose (50 μg of mRNA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.3 ml type 5 adenovirus vector for low-dose; 0.5 ml type 5 adenovirus vector for high-dose)
Number of subjects: 40
Study: 37898434

Group type: EXPERIMENTAL
Intervention: Wholegrain oats and rye (WG)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Refined grain (RG)
Number of subjects: 55